Emerging Treatments and Advances in Novel Cancer Therapies for Practicing Physicians and Healthcare Professionals - Module 3

Target Audience:

This webcast is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new developments for treatment of solid tumors and hematological malignancies. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Program Overview

This webcast is intended to improve care of patients with hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change. In addition to chemotherapy and targeted therapy of solid tumors and hematological malignancies, this symposium will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Hardware/Software Requirements

Recommends version 6.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of content. These activities will be marked as such and will provide links to the required software. Required software may include:
Macromedia Flash
Apple QuickTime
Adobe Acrobat
Microsoft PowerPoint
Windows Media Player
RealNetworks RealOne Player
VLC Media Player

Medium: Internet
Estimated time to complete: 1.5 hours (90 min)
CME Provider contact information: To contact CME provider, call 214 820 2317

CME Provider Privacy Policy and Contact Information

A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 1-214-820-2317.

COURSE VIEWING REQUIREMENTS

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this webcast. During the period April 21, 2014 through April 21, 2015, participants must read all of the material and study the educational webcast.

INSTRUCTIONS FOR COURSE PARTICIPATION
This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.

Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.

Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.

Participants must receive a test score of 100% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a letter of credit.

If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.

LETTER OF CREDIT & TRANSCRIPTS
After submitting the webcast evaluation, you may access your letter of credit by selecting "Your Certificates" on the left navigation bar.

Select "Credit" to view letters of credit onscreen and print from your browser. You may print the letter of credit, but you may not alter the letter of credit.

Your credits will be tallied and may be viewed by selecting "View your transcripts" in the "Your Account" area.

Accreditation:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The A. Webb Roberts Center for CME of Baylor Health Care System designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing:

Fredrick B. Hagemeister, MD,
Professor of Hematology/Oncology,
Department of Lymphoma/ Myeloma,
The University of Texas MD Anderson Cancer Center,
Houston, TX

Elias Jabbour MD,
Associate Professor,
Department of Leukemia,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center,
Houston, TX

Joseph Mikhael, MD,
Consultant Hematologist,
Mayo Clinic,
Associate Professor,
Mayo College of Medicine,
Scottsdale, AZ

Objectives:

  • Prescribe novel treatment options for lymphoma
  • Utilize recent clinical data on the use of novel regimens in the treatment of leukemia
  • Educate patients on standard therapy and novel agent combinations in the treatment of multiple myeloma

Financial Disclosure:

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Name of Faculty or Presenter

Reported Financial Relationship

Fredrick B. Hagemeister, MD

No relevant financial relationships

Elias Jabbour MD

Research Funding: BMS, Novartis, Ariad, Pfizer, GSK

Joseph Mikhael, MD

No relevant financial relationships

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Name of Planner or Manager

Reported Financial Relationship

Anthony Tolcher, MD

Advisory and consultant agreements: Abbott, Abgenomics, Abraxis, Actavis, Adnexus , Ambit Bioscience, Amgen, AP Pharma, Aragon Pharmaceuticals,  Ariad Pharmaceuticals, Arresto Biosciences, Astellas, Astex, BayerHealthCare, Bind Biosciences,  BMS, Celator, Celgene, Clovis, Couger Biotechnology, Curis, Complete Genomics, Cytomx, Daichii Sankyo, Dendreon Corporation, DeNovo, Dicerna, Eisai, Eli Lilly, EMD-Serono, Inc., Endo Pharmaceuticals, Enzon, Everest, Exelixis, Five Prime Therapeutics, Galapagos NV, Genentech,  Geron, GlasoSmithkline, HUYA Bioscience International, Inovio, Icon Clinical Research, Insert Therapeutics, Intellikine, Invivis, Jansson Global Services, LLC, Johnson & Johnson, Merck,  MethylGene, Micromet, Nantworks, Nektar,  Neumedicines,  Novartis, Oncomed, OncoGenix, Onyx, Otsuka, Pfizer,  Pharmacyclics, PPD Development, Presicision Health Holdings, ProNai,  Regeneron Pharmaceuticals, Sanofi-Aventis, Spectrum, Sunovion, Symphogen, Triphase Accelerator Corp,   Vaccinex, Veeda Oncology, Zyngeniz

Kamatham A. Naidu, PhD (CancerNet)

No relevant financial relationships

All other individuals in a position to control content have no relevant financial relationships to disclose.